Zymeworks rejects All Blue Capital's $773 million buyout bid – Reuters

Zymeworks rejects All Blue Capital's $773 million buyout bid – Reuters

May 20 (Reuters) – Zymeworks Inc (ZYME.N) said on Friday its board had rejected investment firm All Blue Capital’s $773 million acquisition offer, saying it undervalued the cancer therapy developer.
Reuters in April reported All Blue’s $10.50 per share bid to Zymeworks that represented a 116% premium to the stock’s last closing price at that time. read more
Shares of Canada-based Zymeworks – which develops antibody treatments for types of cancer and has no approved products on the market – had lost nearly 70% of their value in 2022 before the offer.
Shares of biotech companies have had a rough few months, with investors targeting the private markets more than the public, as equity markets suffer from fears of aggressive monetary policy tightening to tame soaring inflation.
"This non-binding, unsolicited activist proposal was timed opportunistically during a period of substantial market dislocation, and prior to several important near-term events," Zymeworks Chief Executive Officer Kenneth Galbraith said.
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source


Leave a Reply

Your email address will not be published.